Structure Therapeutics (GPCR) Income Statement (2022 - 2026)
Income Statement report data from Mar 31, 2022 to Mar 31, 2026 for Structure Therapeutics (GPCR).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||
Research And Development | 67M (-3.17%) | 69M (+16.44%) | 59M (+7.82%) | 55M (+27.62%) | 43M (+28.01%) | 33M (+2.73%) | 33M (+47.85%) | 22M (+6.62%) | 21M (+18.04%) | 18M (-9.74%) | 19M (+47.72%) | 13M (+43.45%) | 9.16M (-10.02%) | 10M (+19.91%) | 8.49M |
Selling General And Administrative | 23M (+30.17%) | 18M (+18.72%) | 15M (-5.97%) | 16M (+17.11%) | 13M (-0.96%) | 14M (+2.49%) | 13M (+17.48%) | 11M (-0.62%) | 11M (+31.40%) | 8.63M (+31.16%) | 6.58M (+1.08%) | 6.51M (+84.42%) | 3.53M (-6.61%) | 3.78M (-15.25%) | 4.46M |
Operating Expenses | 89M | -23.99M | 74M (+4.74%) | 70M (+25.11%) | 56M (+19.66%) | 47M (+2.66%) | 46M (+37.58%) | 33M (+4.06%) | 32M (+22.45%) | 26M (+0.62%) | 26M (+32.26%) | 20M (+54.85%) | 13M (-9.10%) | 14M (+7.80%) | 13M |
Depreciation And Amortization | 580K (-45.28%) | 1.06M | - | - | 270K (-64.94%) | 770K | - | - | 220K | - | - | 70K | - | - | 70K |
Operating Income | |||||||||||||||
Operating Income | -89.38M | 24M | -73.79M (+4.74%) | -70.45M (+25.11%) | -56.31M (+19.66%) | -47.06M (+2.66%) | -45.84M (+37.58%) | -33.32M (+4.09%) | -32.01M (+22.46%) | -26.14M (+0.58%) | -25.99M (+32.26%) | -19.65M (+54.85%) | -12.69M (-9.10%) | -13.96M (+7.80%) | -12.95M |
Ebit | -89.38M | 24M | -73.79M (+4.74%) | -70.45M (+25.11%) | -56.31M (+19.66%) | -47.06M (+2.66%) | -45.84M (+37.58%) | -33.32M (+4.09%) | -32.01M (+22.46%) | -26.14M (+0.58%) | -25.99M (+32.26%) | -19.65M (+54.85%) | -12.69M (-9.10%) | -13.96M (+7.80%) | -12.95M |
EBITDA | -88.80M | 7.94M | -65.60M (+6.63%) | -61.52M (+9.78%) | -56.04M (-14.55%) | -65.58M (+93.57%) | -33.88M (+30.41%) | -25.98M (-18.28%) | -31.79M (+35.51%) | -23.46M (+1.30%) | -23.16M (+18.28%) | -19.58M (+58.67%) | -12.34M (-11.10%) | -13.88M (+7.76%) | -12.88M |
Net Income | |||||||||||||||
Income Before Tax | -75.78M | 33M | -65.60M (+6.63%) | -61.52M (+31.65%) | -46.73M (+28.59%) | -36.34M (+7.26%) | -33.88M (+30.41%) | -25.98M (-0.12%) | -26.01M (+10.87%) | -23.46M (+1.30%) | -23.16M (+29.03%) | -17.95M (+45.46%) | -12.34M (-11.10%) | -13.88M (+6.61%) | -13.02M |
Income Tax Expense | 190K (+11.76%) | 170K (+54.55%) | 110K (-21.43%) | 140K (+40.00%) | 100K (-28.57%) | 140K (+55.56%) | 90K (+80.00%) | 50K (+66.67%) | 30K (-92.68%) | 410K (+241.67%) | 120K (+300.00%) | 30K (-57.14%) | 70K (+16.67%) | 60K (0.00%) | 60K |
Net Income From Continuing Operations | -75.97M | 33M | -65.71M (+6.57%) | -61.66M (+31.67%) | -46.83M (+28.37%) | -36.48M (+7.36%) | -33.98M (+30.54%) | -26.03M (-0.04%) | -26.04M (+9.14%) | -23.86M (+2.49%) | -23.28M (+29.48%) | -17.98M (+44.77%) | -12.42M (-10.97%) | -13.95M (+6.65%) | -13.08M |
Net Income | -75.97M | 33M | -65.71M (+6.57%) | -61.66M (+31.67%) | -46.83M (+28.37%) | -36.48M (+7.36%) | -33.98M (+30.54%) | -26.03M (-0.04%) | -26.04M (+9.14%) | -23.86M (+2.49%) | -23.28M (+29.48%) | -17.98M (+44.77%) | -12.42M (-10.97%) | -13.95M (+6.65%) | -13.08M |
Comprehensive Income Net Of Tax | -79.22M (-43.84%) | -141.06M (+116.18%) | -65.25M (+5.06%) | -62.11M (+32.35%) | -46.93M (-61.57%) | -122.13M (+298.47%) | -30.65M (+15.97%) | -26.43M (-0.83%) | -26.65M (+12.07%) | -23.78M (-0.17%) | -23.82M (+34.42%) | -17.72M (+42.10%) | -12.47M (-10.93%) | -14.00M (+6.71%) | -13.12M |